PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
Status: Recruiting
Location: See all (46) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 85
Healthy Volunteers: f
View:
• Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
• Minimum BCVA is required in the study eye
Locations
United States
Arizona
Belite Study Site
RECRUITING
Phoenix
California
Belite Study Site
NOT_YET_RECRUITING
Arcadia
Belite Study Site
RECRUITING
Beverly Hills
Belite Study Site
RECRUITING
Huntington Beach
Belite Study Site
RECRUITING
Los Angeles
Belite Study Site
RECRUITING
Palo Alto
Belite Study Site
RECRUITING
San Diego
Florida
Belite Study Site
NOT_YET_RECRUITING
Lakeland
Maryland
Belite Study Site
RECRUITING
Hagerstown
Minnesota
Belite Study Site
RECRUITING
Saint Louis Park
North Carolina
Belite Study Site
RECRUITING
Cary
Belite Study Site
RECRUITING
Durham
Belite Study Site
RECRUITING
Wake Forest
New York
Belite Study Site
RECRUITING
Westbury
Oregon
Belite Study Site
RECRUITING
Portland
Pennsylvania
Belite Study Site
RECRUITING
Philadelphia
Belite Study Site
RECRUITING
Sewickley
Tennessee
Belite Study Site
RECRUITING
Germantown
Texas
Belite Study Site
RECRUITING
Abilene
Belite Study Site
NOT_YET_RECRUITING
Dallas
Belite Study Site
RECRUITING
San Antonio
Virginia
Belite Study Site
RECRUITING
Warrenton
Other Locations
Australia
Belite Study Site
RECRUITING
Adelaide
Belite Study Site
RECRUITING
Brisbane
Belite Study Site
RECRUITING
Chatswood
Belite Study Site
RECRUITING
Crawley
Belite Study Site
RECRUITING
East Melbourne
Belite Study Site
RECRUITING
Strathfield
China
Belite Study Site
RECRUITING
Beijing
Belite Study Site
RECRUITING
Beijing
Belite Study Site
NOT_YET_RECRUITING
Beijing
Belite Study Site
RECRUITING
Chengdu
Belite Study Site
RECRUITING
Guandong
Belite Study Site
NOT_YET_RECRUITING
Zhejiang
France
Belite Study Site
RECRUITING
Dijon
Belite Study Site
RECRUITING
Écully
Belite Study Site
RECRUITING
Lyon
Belite Study Site
RECRUITING
Marseille
Switzerland
Belite Study Site
RECRUITING
Basel
Belite Study Site
RECRUITING
Lausanne
Taiwan
Belite Study Site
RECRUITING
Taichung
Belite Study Site
RECRUITING
Taipei
Belite Study Site
RECRUITING
Taoyuan District
United Kingdom
Belite Study Site
RECRUITING
Great Yarmouth
Belite Study Site
RECRUITING
Harrow
Belite Study Site
RECRUITING
London
Contact Information
Primary
Belitebio Clinical Operations
clinicaltrial@belitebio.com
+886 972 080 097
Time Frame
Start Date: 2023-07-27
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 429
Treatments
Experimental: LBS-008, Tinlarebant
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Belite Bio, Inc